Syndax Pharmaceuticals Inc expected to post a loss of 98 cents a share - Earnings Preview

Syndax Pharmaceuticals

03/05/2024 13:33

* Syndax Pharmaceuticals Inc  SNDX.OQ   SNDX.O  is expected
to show no change in quarterly revenue when it reports 
results on May 8 for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Syndax Pharmaceuticals
Inc is
for a loss of 98 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is $35.00​, above​ its last closing price
of $21.86. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.97       -0.99      -1.00     Missed  -0.6
 Sep. 30 2023  -0.80       -0.80      -0.73     Beat    8.2
 Jun. 30 2023  -0.73       -0.73      -0.64     Beat    12.6​
 Mar. 31 2023  -0.60       -0.60      -0.59     Beat    1
 ​​Dec.        -0.65       -0.65      -0.62     Beat    4.4
 31 2022                                                
 Jan. 1 0001   -0.64       -0.63      -0.58     Beat    8.7​
 Jun. 30 2022  -0.66       -0.64      -0.62     Beat    2.6
 Mar. 31 2022  -0.63       -0.63      -0.63     Met     0.8
 This summary was machine generated May 3 at 12:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)